{"entity":{"id":"fyn","kind":"target","name":"FYN","aka":["FYN proto-oncogene, Src family tyrosine kinase","Tyrosine-protein kinase Fyn","MGC45350"],"tldr":"FYN (Tyrosine-protein kinase Fyn) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma, Leukaemia, Myeloproliferative neoplasms and 2 more.","summary":"Non-receptor tyrosine-protein kinase that plays a role in many biological processes including regulation of cell growth and survival, cell adhesion, integrin-mediated signalling, cytoskeletal remodeling, cell motility, immune response and axon guidance. Inactive FYN is phosphorylated on its C-terminal tail within the catalytic domain. Following activation by PKA, the protein subsequently associates with PTK2/FAK1, allowing PTK2/FAK1 phosphorylation, activation and targeting to focal adhesions.\n\nOpen Targets scores its association with cancer at 0.74 (direct and indirect evidence; datatypes clinical 0.96, affected pathway 0.92, literature 0.97, genetic association 0.00, animal model 0.42).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:4037","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4037"},{"label":"UniProt P06241","url":"https://www.uniprot.org/uniprotkb/P06241/entry"},{"label":"NCBI Gene 2534","url":"https://www.ncbi.nlm.nih.gov/gene/2534"},{"label":"Ensembl ENSG00000010810","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000010810"},{"label":"Sakata-Yanagimoto et al., Nat Genet 2014: somatic RHOA G17V in angioimmunoblastic T-cell lymphoma","url":"https://doi.org/10.1038/ng.2872"},{"label":"Palomero et al., Nat Genet 2014: recurrent mutations in epigenetic regulators, RHOA and FYN in peripheral T-cell lymphoma","url":"https://doi.org/10.1038/ng.2873"}],"tags":["cancer-genes-wave"],"related":["open-targets"],"cancers":["non-hodgkin-lymphoma","leukaemia","myeloproliferative-neoplasms","cml","all-leukemia"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":["epigenetic-reprogramming","clonal-haematopoiesis"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.97. Evidence tier \"approved-drug\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate.","Lymphoma, RHOA G17V and the epigenetic mutations of T-follicular-helper lymphoma: A single substitution, G17V, in the small GTPase RHOA produces a protein that does not bind GTP and that blocks the wild-type protein as well. It is specific to the tumour cell, whereas the TET2 mutations that accompany it are found in non-tumour haematopoietic cells too, which places the TET2 lesion earlier, in the stem cell, and makes this lymphoma a disease that grows out of clonal haematopoiesis. Frequency: RHOA G17V in 68% of angioimmunoblastic T-cell lymphoma samples, with every G17V case also carrying a TET2 mutation (Sakata-Yanagimoto 2014); independently, in 22 of 35 angioimmunoblastic cases, 67%, and 8 of 44 peripheral T-cell lymphoma not otherwise specified, 18%, alongside recurrent TET2, DNMT3A and IDH2 mutations and less frequent FYN, ATM, B2M and CD58 lesions (Palomero 2014). What it changes about treatment: Not through an approved test. The hypomethylating agents are used in this disease on the strength of the TET2 and DNMT3A biology rather than on a mutation result, and azacitidine-containing regimens have shown activity in T-follicular-helper histology specifically."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"FYN","role":["drug-target"],"evidenceTier":"approved-drug","sources":[{"label":"HGNC HGNC:4037","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4037","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P06241","url":"https://www.uniprot.org/uniprotkb/P06241/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"Open Targets ENSG00000010810","url":"https://platform.opentargets.org/target/ENSG00000010810/associations","note":"association with cancer (MONDO_0004992) 0.74; per-cancer scores at or above 0.5: acute lymphoblastic leukaemia 0.56, non-Hodgkin lymphoma 0.69, chronic myelogenous leukaemia, BCR-ABL1 positive 0.60, myeloproliferative neoplasm 0.61, leukaemia 0.62 (GraphQL API, CC0)"}],"specificity":"broadly-expressed","distribution":"few-types","specificityNote":"Broadly expressed or essential: HPA finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA FYN: RNA low tissue specificity; blood lineage group enriched (NK-cells 69 nTPM, T-cells 175 nTPM); high antibody staining in 3 normal tissues; highest cancer staining lymphoma (4 of 12 high). Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Lymphoma, Leukaemia, Myeloid neoplasms); Open Targets associates it with 2 specific cancer types at or above 0.5 (chronic myeloid leukemia, acute lymphoblastic leukemia). (Rule 7 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"Human Protein Atlas FYN tissue","url":"https://www.proteinatlas.org/ENSG00000010810-FYN/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000010810 associations","url":"https://platform.opentargets.org/target/ENSG00000010810/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:4037","ensembl":"ENSG00000010810","uniprot":"P06241","entrez":"2534","firstDescribed":1986,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Kawakami et al, Mol. Cell. Biol, 1986, \"Isolation and oncogenic potential of a novel human src-like gene\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/3099169/","biology":"Non-receptor tyrosine-protein kinase that plays a role in many biological processes including regulation of cell growth and survival, cell adhesion, integrin-mediated signalling, cytoskeletal remodeling, cell motility, immune response and axon guidance. Inactive FYN is phosphorylated on its C-terminal tail within the catalytic domain. Following activation by PKA, the protein subsequently associates with PTK2/FAK1, allowing PTK2/FAK1 phosphorylation, activation and targeting to focal adhesions. Involved in the regulation of cell adhesion and motility through phosphorylation of CTNNB1 (beta-catenin) and CTNND1 (delta-catenin). Regulates cytoskeletal remodeling by phosphorylating several proteins including the actin regulator WAS and the microtubule-associated proteins MAP2 and MAPT. Promotes cell survival by phosphorylating AGAP2/PIKE-A and preventing its apoptotic cleavage. Location: Cytoplasm; Nucleus; Cell membrane; Perikaryon (UniProt). Locus 6q21 (HGNC).","whereFound":["Non-Hodgkin lymphoma: Open Targets association 0.69 with non-Hodgkin lymphoma (MONDO_0018908)","Leukaemia: Open Targets association 0.62 with leukaemia (MONDO_0005059)","Myeloproliferative neoplasms: Open Targets association 0.61 with myeloproliferative neoplasm (MONDO_0020076)","Chronic myeloid leukaemia: Open Targets association 0.60 with chronic myelogenous leukaemia, BCR-ABL1 positive (MONDO_0011996)","Acute lymphoblastic leukaemia: Open Targets association 0.56 with acute lymphoblastic leukaemia (MONDO_0004967)"],"targetClass":"kinase","prevalence":[]},"route":"/targets/fyn/","neighbours":{"collection":[{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/"},{"id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/"},{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"},{"id":"angioimmunoblastic-t-cell-lymphoma","kind":"cancer","name":"Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma)","route":"/cancers/angioimmunoblastic-t-cell-lymphoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"},{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/"}],"pathway":[{"id":"clonal-haematopoiesis","kind":"pathway","name":"Clonal haematopoiesis (CHIP)","route":"/pathways/clonal-haematopoiesis/"},{"id":"epigenetic-reprogramming","kind":"pathway","name":"Epigenetic reprogramming","route":"/pathways/epigenetic-reprogramming/"}],"biomarker":[{"id":"rhoa-g17v","kind":"biomarker","name":"RHOA G17V","route":"/biomarkers/rhoa-g17v/"}]}}